Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2026 07:30 ET | Source: Zelluna ASA

Zelluna ASA - Grant of Share Options

Oslo, 5 February 2026: On the basis of the authorization granted by the General Meeting on 29 April 2025 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to...
February 05, 2026 03:30 ET | Source: Zelluna ASA

Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation

Oslo, Norway, 5 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a...
February 03, 2026 02:00 ET | Source: Zelluna ASA

Zelluna promotes Emilie Gauthy to Chief Technology Officer

Oslo, Norway, 03 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers,...
February 03, 2026 02:00 ET | Source: Zelluna ASA

Zelluna utnevner Emilie Gauthy til Chief Technology Officer

Oslo, Norge – 3. februar 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte Natural Killer (TCR-NK) celleterapier for behandling av kreft, kunngjorde...
January 15, 2026 06:23 ET | Source: Zelluna ASA

Zelluna ASA: Approval and publication of prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
December 17, 2025 11:26 ET | Source: Zelluna ASA

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours

On track for initial clinical data in mid-2026Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumours Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a...
December 17, 2025 11:26 ET | Source: Zelluna ASA

Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk studie i Storbritannia for første studie på mennesker av ZI-MA4-1 (ZIMA-101), verdens første MAGE-A4-rettede TCR-NK celleterapi for solide kreftformer.

Forventer første kliniske data fra midten av 2026Markerer et viktig skritt mot skalerbare, tilgjengelige "off-the-shelf" celleterapier for solide kreftformer Oslo, Norge, 17. desember 2025 – Zelluna...
December 16, 2025 06:37 ET | Source: Zelluna ASA

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today...
December 12, 2025 07:02 ET | Source: Zelluna ASA

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial

On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important step in developing scalable and accessible ‘off-the-shelf’ cell therapy for...
December 09, 2025 03:36 ET | Source: Zelluna ASA

Zelluna ASA: Cancellation of subsequent repair offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...